Psyllium Husk
drugOn this page
Also known as Psyllium 85%unspecifiedPsyllium hydrophilic mucilloidPsyllium mucilloidPsyllium seed coat
Summary
Psyllium Husk (CHEMBL2108126) is a phase-3 clinical-stage unknown; indicated across 1 condition including constipation disorder.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 1 condition
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108126 |
| Name | Psyllium Husk |
| Type | Unknown |
| Max phase | 3 |
Also known as: Psyllium 85%, Psyllium husk, unspecified, Psyllium hydrophilic mucilloid, Psyllium mucilloid, Psyllium seed coat, PSYLLIUM HUSK
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| constipation disorder | 2 | MONDO:0002203 | HP:0002019 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 3 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05867550 | PHASE4 | COMPLETED | To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea |
| NCT06256276 | Not specified | COMPLETED | Nutritional Therapy for Autonomic Dysfunction in Elderly Heart Failure Patients |
| NCT06724198 | Not specified | COMPLETED | Bowel Dysfunction After Low Rectal Resection. An Pilot Study Using Psyllium Husk In Rectal Cancer Patients. |
| NCT06789471 | Not specified | COMPLETED | The Effects of Psyllium Seed on Body Weight and Metabolic Syndrome Indicators in Patients with Schizophrenia |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.